A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
October 12, 2012|Oncology Practice
Author and Disclosure Information
Objectives: Onartuzumab is an investigational monoclonal antibody that has been shown to improve outcomes of patients with high Met protein levels. Overall survival is the primary outcome measure.
Key entry or exclusion criteria: Patients must have incurable stage IIIb/IV non–small cell lung cancer and be confirmed as Met diagnostic-positive.
Locations: 187 sites.
Goal: 480 patients.
Study sponsor: Genentech in collaboration with Hoffman-La Roche
Link for more information: https://clinicaltrials.gov/ct2/show/NCT01456325
NIH clinical trial identifier: NCT01456325